- Conditions
- Dry Eye Disease (DED)
- Interventions
- DFL24498, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Interventions
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
- Conditions
- Dry Eye
- Interventions
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Neurotrophic Keratopathy
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 29
- States / cities
- Laguna Hills, California • Loma Linda, California • Colorado Springs, Colorado + 25 more
- Conditions
- Dry Eye, Dry Eye Syndromes
- Interventions
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Presbyopia
- Interventions
- Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
- Drug · Other
- Lead sponsor
- Ocuphire Pharma, Inc.
- Industry
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
- Drug
- Lead sponsor
- Mitotech, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Presbyopia, Near Vision, Refractive Error, Eye Diseases
- Interventions
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle
- Drug
- Lead sponsor
- LENZ Therapeutics, Inc
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Chandler, Arizona • Mesa, Arizona + 35 more